US M&A and equity raisings
3,392 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
Deals dated after 30 September 2026 are still being collected.
58 deals · US$48bndisclosed · Life Sciences · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Sep 2026 | Standard BioTools Mass Cytometry business | Standard BioTools | Element Biosystems | Asset sale | Announced | 5.5 | Life Sciences+1 | Maynard Nexsen (buy-side) |
| Sep 2026 | Lifecore Biomedical | – | Webster Equity Partners | Acquisition | Announced | 663.7 | Pharma Services+2 | Bourne Capital Partners (sell-side)Craig-Hallum (sell-side)Ballard Spahr (sell-side)Zukerman Gore Brandeis & Crossman (sell-side)Morgan Stanley (buy-side)Goodwin (buy-side) |
| Sep 2026 | Agilex Biolabs | Healius | Novotech Health Holdings | Acquisition | Announced | 114.0 | Healthcare+1 | UBS (sell-side)Mallesons (sell-side) |
| Sep 2026 | Firma Data Services | Firma Clinical Research | Everest Clinical Research | Asset sale | Completed | – | Clinical Trial Services+1 | Edgemont Partners (sell-side) |
| Sep 2026 | Cellipont Bioservices | – | – | Merger | Completed | – | Pharma Services+2 | William Blair |
| Sep 2026 | Prolytix | Edgewater | VION | Acquisition | Announced | – | Pharma Services+1 | Stout (sell-side) |
| Aug 2026 | Precision Medicine Group | Blackstone | McKesson | Acquisition | Announced | 2,250.0 | Clinical Trial Services+1 | Debevoise & Plimpton (sell-side)Centerview Partners (sell-side)Davis Polk (buy-side) |
| Aug 2026 | BWXT Medical business | BWX Technologies | Nordic Capital | Asset sale | Pending | 800.0 | Radiopharmaceuticals+2 | Solomon Partners (sell-side)Stikeman Elliott (sell-side)Kirkland & Ellis (buy-side)McCarthy Tétrault (buy-side) |
| Aug 2026 | MIMETAS | – | BRUKER | Acquisition | Completed | – | Life Sciences+1 | Raymond James |
| Aug 2026 | NovaBone Products | Halma | Isto Biologics | Acquisition | Completed | 60.0 | Medtech+1 | Baird (buy-side) |
| Jul 2026 | Avisoft Bioacoustics | – | Lafayette Instrument | Acquisition | Completed | – | Life Sciences+2 | Vedder Price (buy-side)RSM (buy-side) |
| Jul 2026 | MYOS Corp | – | PetIQ | Acquisition | Completed | – | Supplements+2 | Davis Graham (sell-side)Davis Polk (buy-side)Lincoln International (buy-side) |
| Jul 2026 | ArisGlobal | Nordic Capital | Dassault Systèmes | Acquisition | Announced | 2,000.0 | Healthcare Software+2 | Evercore (sell-side)Jefferies (sell-side)Kirkland & Ellis (sell-side)Sullivan & Cromwell (buy-side) |
| Jul 2026 | BioLife Solutions | – | Repligen | Acquisition | Announced | 1,500.0 | Life Sciences+1 | Centerview Partners (sell-side)K&L Gates (sell-side)Goodwin (buy-side)Perella Weinberg Partners (buy-side)Goldman Sachs (buy-side) |
| Jul 2026 | Personalis | – | Tempus AI | Acquisition | Announced | 1,900.0 | Diagnostics+2 | Centerview Partners (sell-side)TD Securities (sell-side)Cooley (sell-side)Morgan Stanley (buy-side)Latham & Watkins (buy-side) |
| Jul 2026 | Life Sciences & Healthcare segment | Clarivate | Altaris | Asset sale | Announced | 600.0 | Healthcare Software+2 | Davis Polk (sell-side)Morgan Stanley (sell-side)Hogan Lovells Cadwalader (sell-side)Joele Frank, Wilkinson Brimmer Katcher (sell-side)Kirkland & Ellis (buy-side) |
| Jul 2026 | DCM BioServices | – | Surplus Solutions | Acquisition | Announced | – | Life Sciences+1 | McDermott Will & Schulte (buy-side) |
| Jul 2026 | MeiraGTx Holdings | – | Oberland Capital Management | Stake | Announced | – | Biotech+1 | Latham & Watkins (sell-side) |
| Jul 2026 | Momentum Life Sciences | – | Parthenon Capital Partners | Stake | Completed | – | Healthcare Software+1 | William Blair |
| Jul 2026 | LaCorium Health | founders of LaCorium Health | Prestige Consumer Healthcare | Acquisition | Completed | – | Healthcare+1 | Addisons (sell-side)Pitcher Partners (buy-side) |
| Jul 2026 | B Medical Systems | Azenta | Thelema S.à r.l. | Asset sale | Completed | – | Medtech+1 | William Blair |
| Jun 2026 | Bio-Techne | – | Merck KGaA | Acquisition | Pending | 11,300.0 | Life Sciences+1 | Goldman Sachs (sell-side)Sidley Austin (sell-side)Joele Frank, Wilkinson Brimmer Katcher (sell-side)Guggenheim Securities (buy-side)J.P. Morgan (buy-side)Sullivan & Cromwell (buy-side) |
| Jun 2026 | Sangamo Therapeutics capsid delivery, zinc finger, modular integrase platforms and prion disease program | Sangamo Therapeutics | Eli Lilly and Company | Asset sale | Completed | – | Biotech+1 | Raymond JamesPaul, Weiss (buy-side) |
| Jun 2026 | Simulations Plus | – | Affiliates of Altaris | Acquisition | Announced | 375.0 | Life Sciences+2 | Morgan Stanley (sell-side)Procopio, Cory, Hargreaves & Savitch (sell-side)Bass, Berry & Sims (buy-side)Truist Securities (buy-side)J.P. Morgan (buy-side)Kirkland & Ellis (buy-side)Latham & Watkins (buy-side) |
| Jun 2026 | Ignite Proteomics | Aditxt | Proposed Ignite Proteomics Inc. holding company | Merger | Pending | 150.0 | Life Sciences+2 | Ladenburg Thalmann |
| Jun 2026 | Kalderos | – | Model N | Acquisition | Announced | – | Healthcare Software+2 | Kirkland & Ellis (buy-side) |
| Jun 2026 | kneat.com | – | Thoma Bravo, L.P. | Acquisition | Pending | 453.6 | Vertical SaaS+1 | Kirkland & Ellis (buy-side) |
| Jun 2026 | Helio Health Group | – | WestView Capital Partners | Stake | Completed | – | AI+1 | Latham & Watkins (buy-side) |
| May 2026 | Ennov Group | – | Bregal Sagemount | Stake | Announced | – | Healthcare Software+2 | Proskauer RoseGoodwin (buy-side) |
| May 2026 | Sutter Instrument Corp. | – | Lafayette Instrument | Acquisition | Completed | – | Manufacturing+2 | EC M&A (sell-side)Donahue Fitzgerald (sell-side)Akerman (buy-side)RSM (buy-side) |
| May 2026 | Regenity Biosciences | – | Cinven | Stake | Announced | – | Medtech+1 | Baird (sell-side) |
| Apr 2026 | XOMA Royalty | – | Ligand Pharmaceuticals | Acquisition | Completed | 739.0 | Specialty finance and leasing+2 | Leerink Partners (sell-side)H.C. Wainwright & Co. (sell-side)Gibson Dunn (sell-side)Stifel (buy-side)Citi (buy-side)Paul Hastings (buy-side)Collected Strategies (buy-side) |
| Apr 2026 | Certara Regulatory and Medical Writing business | Certara | Veristat | Asset sale | Announced | 135.0 | Pharma Services+1 | Perella Weinberg Partners (sell-side)Troutman Pepper Locke (sell-side)Guggenheim Securities (buy-side)McDermott Will & Schulte (buy-side) |
| Apr 2026 | EpiVax | – | SV Health Investors | Acquisition | Announced | – | Pharma Services+2 | Morgan Lewis (buy-side) |
| Apr 2026 | Thermo Fisher Scientific's microbiology division | Thermo Fisher Scientific | Astorg | Asset sale | Announced | 1,075.0 | Diagnostics+1 | Cravath, Swaine & Moore (sell-side)Perella Weinberg Partners (sell-side)Latham & Watkins (buy-side)Moelis & Company (buy-side) |
| Apr 2026 | TriNetX | – | Regeneron Pharmaceuticals | Stake | Completed | – | Healthcare Software+2 | William Blair |
| Apr 2026 | Celerion | H.I.G. Capital affiliate | THL Partners | Acquisition | Announced | – | Pharma Services+2 | LazardKirkland & Ellis (buy-side)Paul, Weiss (buy-side) |
| Mar 2026 | Stratis Group | – | Nexus Health | Acquisition | Announced | – | Accounting, legal and consulting+1 | Clearsight Advisors (sell-side)Pillsbury Winthrop Shaw Pittman (sell-side) |
| Mar 2026 | Biocare Medical | – | Agilent Technologies | Acquisition | Announced | 950.0 | Diagnostics+1 | Sullivan & Cromwell (buy-side) |
| Mar 2026 | Lonza Capsules & Health Ingredients division | Lonza Group AG | Lone Star Funds | Asset sale | Announced | – | Pharmaceutical Manufacturing+2 | Kirkland & Ellis (buy-side) |
| Feb 2026 | Bruder Consulting & Venture Group | – | Dark Horse Consulting Group | Acquisition | Completed | – | Accounting, legal and consulting+1 | Goodwin (sell-side)Edgemont Partners (sell-side) |
| Feb 2026 | Laysan Bio | – | Gannet BioChem | Acquisition | Announced | – | Pharma Services+2 | Goodwin (buy-side) |
| Feb 2026 | Dutscher Group | – | Vivo Capital | Acquisition | Announced | – | Life Sciences+1 | Sidley Austin (buy-side)Mayer Brown (buy-side) |
| Jan 2026 | Ganymede | – | Apprentice.io | Acquisition | Announced | – | Software+1 | Cooley (buy-side) |
| Jan 2026 | StarLIMS | – | Turn/River Capital | Stake | Announced | – | Software+2 | |
| Jan 2026 | Verana Health | – | – | Merger | Announced | – | Healthcare Software+2 | BofA Securities (sell-side)Wilson Sonsini Goodrich & Rosati (buy-side) |
| Jan 2026 | Aktana | – | PharmaForceIQ | Asset sale | Announced | – | Healthcare Software+2 | Canaccord Genuity |
| Jan 2026 | PTC Therapeutics' remaining royalty on Roche's Evrysdi | PTC Therapeutics | Royalty Pharma | Asset sale | Announced | 240.0 | Specialty finance and leasing+2 | Goodwin (buy-side) |
| Jan 2026 | Evidinno Outcomes Research | – | United BioSource | Acquisition | Completed | – | Pharma Services+2 | Fairmount Partners (sell-side) |
| Jan 2026 | BioRender | – | Dimension Capital | Stake | Announced | 900.0 | Software+2 | Sidley Austin (sell-side) |
Deals come from SEC filings (merger proxies, tender offers, 8-K announcements and IPO prospectuses), the deal pages and transaction lists of law firms and banks, companies' press releases and the press. How the data is built